Feed SCYX
SC
SCYNEXIS, Inc. SCYX · NASDAQ
$3.66 -0.27% (-$0.01)
Summary
57 / 100 · Bulios Score
Valuation 100Growth 100Profitability 20Quality 3Debt 100Stability 21
What speaks for it
- Revenue grew by 59% a year over the last 3 years.
- It holds more cash than debt: $10.5M against $1.95M.
What to watch
- The company made a loss over the last 12 months.
- It passes only 2 of the 9 points of the Piotroski financial health test.
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Score in detailPrice
Is it expensive?
Looks cheapThe company made a loss over the last 12 months, so there is no profit to set the price against.
Valuation in detailIs it growing?
Yes, fastRevenue (USD)
2021202220232024202520262027
Diluted EPS (USD)
2021202220232024202520262027
- Analyst estimate
Revenue grew by 59% a year over the last 3 years.
Growth in detailDoes it make money?
PoorlyOver the last 12 months it made a loss of $10.2M.
Profitability in detailIs it financially healthy?
YesCash and short-term investments $54.1M
Debt $1.95M
Free cash flow over 12 months -$13.3M
Over the last 12 months it spent more cash than it brought in. It holds more cash than debt.
Financial health in detailDoes it pay a dividend?
NoIt pays no dividend.
Dividends in detailWhat do analysts expect?
Mildly positive- Buy 13
- Hold 1
- Sell 0
No analyst has published a price target.
93% of the analysts recommend buying.
Analysts in detailWhat does it earn on?
Fiscal year 2025By product
- License and Service 93%
- Product 7.0%
By region
- Other Non-US 100%
License and Service brings in 93% of revenue.
Segments in detail